CHEMM ChemoMetec

Appointment of new CEO

Appointment of new CEO

ANNOUNCEMENT NO. 255 (Changed category - Inside information)



 Appointment of new CEO

The Board of Directors of ChemoMetec has decided to appoint the company's current COO Martin Helbo Behrens as new CEO, effective as of today.

The decision is based on the Board’s assessment that ChemoMetec in the current phase of the company's development needs a different composition of executive management skills. Therefore, the board has entered into an agreement with the company's current CEO Rasmus Kofoed to resign from his position as of today.

Martin Helbo Behrens, who is 31 years old, has been employed at ChemoMetec for a number of years. He was originally employed as part of Group Finance, but in 2021 he relocated to the USA to take up a position as first COO and then CFO of ChemoMetec's American subsidiary. In these roles he has made a significant contribution to ChemoMetec's high growth and commercial success in the North American market over recent years. After almost three years in the USA, Martin Helbo Behrens returned to ChemoMetec's head office in Allerød as Deputy COO in 2023 and took up the position as COO on 1 February 2024.

With Martin Helbo Behrens' in-depth insight into ChemoMetec's organization, products and markets, and based on the results he has contributed to creating in ChemoMetec, the Board is convinced that Martin Helbo Behrens will be the right profile to head ChemoMetec as CEO in the future.

CEO Martin Helbo Behrens and CFO Niels Høy Nielsen will hereafter form the executive management of ChemoMetec.



For further information

Chairman of the Board Niels Thestrup, ChemoMetec A/S

Phone: (+45) 3370 2000



About ChemoMetec A/S

ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec’s instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec’s customers include some of the world’s leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.

ChemoMetec was founded in 1997 and is listed on the Nasdaq Copenhagen stock exchange. For more information, go to



EN
13/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ChemoMetec

ChemoMetec A S: 3 directors

Two Directors at ChemoMetec A S bought 1,650 shares at between 271.600DKK and 275.800DKK. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...

 PRESS RELEASE

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 306 27. marts 2026 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af CFO Kim Nicolajsens transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20           Om ChemoMetec A/S ChemoMe...

 PRESS RELEASE

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 306 27 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of CFO Kim Nicolajsen in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 20 About ChemoMetec A/S ChemoMetec devel...

 PRESS RELEASE

Notification of managers’ transactions

Notification of managers’ transactions ANNOUNCEMENT NO. 305 27 March 2026 Notification of managers’ transactions ChemoMetec A/S has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in ChemoMetec A/S made by persons discharging managerial responsibilities in ChemoMetec A/S and/or persons closely associated with them. See the transactions of the Chair of ChemoMetec’s Board of Directors Niels Thestrup in the attached PDF document. For further information, please contact: Kim Nicolajsen, CFOTelephone (+45) 48 13 10 2...

 PRESS RELEASE

Indberetning af ledende medarbejderes transaktioner

Indberetning af ledende medarbejderes transaktioner MEDDELELSE NR. 305                 27. marts 2026 Indberetning af ledende medarbejderes transaktioner ChemoMetec A/S har i henhold til artikel 19 i forordning (EU) nr. 596/2014 modtaget nedenstående indberetning om transaktioner i ChemoMetec A/S aktier udført af personer med ledelsesansvar og/eller personer, der er nært knyttet til dem. Se indberetning af bestyrelsesformand Niels Thestrups transaktioner i vedhæftede pdf-dokument. Yderligere oplysninger kan fås ved henvendelse til: Kim Nicolajsen, CFOTelefon: (+45) 48 13 10 20       ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch